HCA Healthcare, Inc. (HCA) earnings date, results and what the price requires
NYSE · SEC CIK 0000860730 · SEC filings checked Oct 16, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 14, 2026 | Announced; figures arrive with the 10-Q | — | — | Filing |
| Mar 31, 2026 | Apr 24, 2026 | $19.11B | $1.62B | $7.15 | Filing |
| Dec 31, 2025 | Jan 27, 2026 | $19.51B | $1.88B | $8.09 | Filing |
| Sep 30, 2025 | Oct 24, 2025 | $19.16B | $1.64B | $6.96 | Filing |
| Jun 30, 2025 | Jul 25, 2025 | $18.61B | $1.65B | $6.83 | Filing |
| Mar 31, 2025 | Apr 25, 2025 | $18.32B | $1.61B | $6.45 | Filing |
| Dec 31, 2024 | Jan 24, 2025 | $18.29B | $1.44B | $5.66 | Filing |
| Sep 30, 2024 | Oct 25, 2024 | $17.49B | $1.27B | $4.88 | Filing |
| Jun 30, 2024 | Jul 23, 2024 | $17.49B | $1.46B | $5.53 | Filing |
What would HCA Healthcare, Inc. have to report for its valuation to change?
At $468.50, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 6.6% a year, to $40.05. On that path the next quarter needs diluted EPS near $7.28, against $6.83 in the quarter ended Jun 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 6.6% | 6.6% |
| EPS needed in final year | $40.05 | $40.05 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. HCA goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.